Jennifer Steel

Dr. Jennifer Steel

1. University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
+1

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2015 in Transplantation
Verified
Journal Article
Closed access
MDMary Amanda Dew
Mary Amanda Dew
EREmily M. Rosenberger
Emily M. Rosenberger
LMLarissa Myaskovsky
Larissa Myaskovsky
ADAndrea F. DiMartini
Andrea F. DiMartini
ADAnnette J. DeVito Dabbs
Annette J. DeVito Dabbs
JGJoel B. Greenhouse
Joel B. Greenhouse
Background Depression and anxiety are common mental health problems in transplant populations. There is mixed evidence concerning whether they increase morbidity and mortality risks after transplantation. If such associations exist, additional risk reduction strategies may be needed. Methods Four bibliographic databases were searched from 1981 through September 2014 for studies prospectively examining whether depression or anxiety (determined with diagnostic evaluations or standardized symptom scales) affected risk for posttransplant mortality, graft loss, acute graft rejection, chronic rejection, cancer, infection, and rehospitalization. Results Twenty-seven studies (10 heart, total n = 1738; 6 liver, n = 1063; 5 kidney, n = 49515; 4 lung, n = 584; 1 pancreas, n = 80; 1 mixed recipient sample, n = 205) were identified. In each, depression and/or anxiety were typically measured before or early after transplantation. Follow-up for outcomes was a median of 5.8 years (range, 0.50-18.0). Depression increased the relative risk (RR) of mortality by 65% (RR, 1.65; 95% confidence interval [95% CI], 1.34-2.05; 20 studies). Meta-regression indicated that risk was stronger in studies that did (vs did not) control for potential confounders (P = .032). Risk was unaffected by type of transplant or other study characteristics. Depression increased death-censored graft loss risk (RR, 1.65; 95% CI, 1.21-2.26, 3 studies). Depression was not associated with other morbidities (each morbidity was assessed in 1-4 studies). Anxiety did not significantly increase mortality risk (RR, 1.39; 95% CI, 0.85-2.27, 6 studies) or morbidity risks (assessed in single studies). Conclusions Depression increases risk for posttransplant mortality. Few studies considered morbidities; the depression-graft loss association suggests that linkages with morbidities deserve greater attention. Depression screening and treatment may be warranted, although whether these activities would reduce posttransplant mortality requires study.

25 August 2016 in Journal of Immigrant and Minority Health
Verified
Journal Article
Closed access
PDF file
JSJennifer Steel
Jennifer Steel
ADAndrea C. Dunlavy
Andrea C. Dunlavy
CHCollette E. Harding
Collette E. Harding
TTTöres Theorell
Töres Theorell

1 April 2017 in Sleep Medicine
Verified
Journal Article
Closed access
KCKevin P. Collins
Kevin P. Collins
DGDavid A. Geller
David A. Geller
MAMichael Antoni
Michael Antoni
DDDrew Michael Donnell
Drew Michael Donnell
ATAllan Tsung
Allan Tsung
JSJennifer Steel
Jennifer Steel

11 March 2016 in Cancer
Verified
Journal Article
Open access
PDF file
JSJennifer Steel
Jennifer Steel
DGDavid A. Geller
David A. Geller
KKKevin H. Kim
Kevin H. Kim
LBLisa H. Butterfield
Lisa H. Butterfield
MSMichael Spring
Michael Spring
ATAllan Tsung
Allan Tsung
BACKGROUND: The aim of this study was to examine the efficacy of a collaborative care intervention in reducing depression, pain, and fatigue and improve quality of life.METHODS: A total of 261 patients with advanced cancer and 179 family caregivers were randomized to a web‐based collaborative care intervention or enhanced usual care. The intervention included the following: 1) a web site with written and audiovisual self‐management strategies, a bulletin board, and other resources; 2) visits with a care coordinator during a physician's appointment every 2 months; and 3) telephone follow‐up every 2 weeks. Primary patient outcomes included measures of depression, pain, fatigue, and health‐related quality of life. Secondary outcomes included Interleukin (IL)‐1α, IL‐1β, IL‐6, and IL‐8 levels, Natural Killer (NK) cell numbers, and caregiver stress and depression.RESULTS: At the baseline, 51% of the patients reported 1 or more symptoms in the clinical range. For patients who presented with clinical levels of symptoms and were randomized to the intervention, reductions in depression (Cohen's d = 0.71), pain (Cohen's d = 0.62), and fatigue (Cohen's d = 0.26) and improvements in quality of life (Cohen's d = 0.99) were observed when compared to those in the enhanced usual car arm at 6 months. Reductions in IL‐6 (φ = 0.18), IL‐1β (φ = 0.35), IL‐1α (φ = 0.19), and IL‐8 (φ = 0.15) and increases in NK cell numbers (φ = 0.23) were observed in comparison with enhanced usual care arm at 6 months. Reductions in caregiver stress (Cohen's d = 0.75) and depression (Cohen's d = 0.37) were observed at 6 months for caregivers whose loved ones were randomized to the intervention arm.CONCLUSIONS: The integration of screening and symptom management into cancer care is recommended. Cancer 2016;122:1270–82. © 2016 American Cancer Society.

1 April 2011 in Psycho-Oncology
Verified
Journal Article
Closed access
PDF file
AMAimee M. Moore
Aimee M. Moore
TGT. Clark Gamblin
T. Clark Gamblin
DGDavid A. Geller
David A. Geller
MYMichael N. Youssef
Michael N. Youssef
KHKristin E. Hoffman
Kristin E. Hoffman
JSJennifer Steel
Jennifer Steel

1 May 2010 in Journal of Pain and Symptom Management
Verified
Journal Article
Closed access
JSJennifer Steel
Jennifer Steel
KKKevin H. Kim
Kevin H. Kim
MDMary Amanda Dew
Mary Amanda Dew
MUMark L. Unruh
Mark L. Unruh
MAMichael H. Antoni
Michael H. Antoni
TGT. Clark Gamblin
T. Clark Gamblin